Background A wide variety of scoring systems have been proposed to assess severity of
psoriasis. Given its importance as a health issue both for patients and health care systems, it …

In a non‐life‐threatening disease such as psoriasis, treatment goals should be referred to
the improvement in severity and extent of the disease and their impact on patients' perceived …

Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …

Background Early clinical studies suggested that the anti–interleukin-17 receptor A
monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two …

Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has
shown superior efficacy to etanercept with similar safety in moderate to severe plaque …

Background Certolizumab pegol, the only Fc-free, PEGylated anti–tumor necrosis factor
biologic, demonstrated clinically meaningful improvements suggestive of a positive risk …

Introduction Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that
demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe …

Background New psoriasis therapies have increased the ability to achieve skin clearance.
However, insufficient evidence exists on the impact of total skin clearance from the patient …

Objectives To compare health-related quality of life (HRQoL) before and after treatment with
etanercept in patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis …

Background BE SURE 1-year results demonstrated the superior efficacy of bimekizumab
compared with adalimumab with no unexpected safety findings. Objectives To provide …